Survodutide
Also known as: BI 456906, GLP-1/glucagon dual agonist
Survodutide (also called BI 456906 or GLP-1/glucagon dual agonist) is a glucagon agonist in the GLP-1 Agonist class. Survodutide is a dual agonist at the glucagon and GLP-1 receptors, acylated for weekly dosing. GLP-1 receptor activation reduces energy intake through central appetite circuits and improves glucose-dependent insulin secretion, while glucagon receptor activation increases hepatic energy expenditure and stimulates fatty-acid oxidation in the liver.
For research use only.
Key Facts
- CAS
- 2805997-46-8
- Molecular Weight (MW)
- ≈4232 g/mol
- Half-life
- ~6 days (once-weekly)
- FDA status
- Investigational New Drug (IND)
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once weekly
- Last updated
- Sep 6, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GLP-1 receptorGlucagon receptor
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 8
- Listed offers
- 8
- Median price per mg
- $12.50/mg
- Typical $9.37–$23.75/mg
Research summary
Investigational dual agonist at the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma and studied in phase 3 trials for obesity and for metabolic dysfunction-associated steatohepatitis. The glucagon component acts directly on hepatocytes to increase energy expenditure and fat oxidation, which is why liver endpoints feature alongside weight. Not FDA-approved for any indication.
Peptide Library's Survodutide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Survodutide dosage chart
Survodutide has no approved dosage. Human dosing comes from Boehringer Ingelheim's registered programme, where 0.6, 2.4, 3.6 and 4.8 mg once weekly were compared in a 46-week phase 2 obesity trial, and doses up to 6.0 mg once weekly were studied in metabolic liver disease and carried into phase 3. Weight loss increased across the dose range, and every dose was reached by protocol-driven escalation under trial monitoring.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.6–6.0 mg once weekly in trials |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 46 weeks in the phase 2 obesity trial |
| Titration | Stepwise escalation to the assigned dose inside the trial protocol. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2 dose-finding trial in obesity (2024)Clinical trial · Phase 2 randomised double-blind placebo-controlled dose-finding trial | Adults aged 18–75 with BMI ≥27 and without diabetes (n=386 treated) | 0.6 mg (n=77), 2.4 mg (n=78), 3.6 mg (n=77) or 4.8 mg (n=77) | Subcutaneous | Once weekly | 46 weeks | Percentage change in body weight — −6.2% at 0.6 mg rising to −14.9% at 4.8 mg | Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. |
| Phase 2 trial in MASH and fibrosis (2024)Clinical trial · Phase 2 randomised placebo-controlled trial | Adults with metabolic dysfunction-associated steatohepatitis and fibrosis | 2.4 mg, 4.8 mg or 6.0 mg | Subcutaneous | Once weekly | Per trial protocol | Improvement in MASH without worsening of fibrosis | A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. |
| Phase 3 obesity trial (2026)Clinical trial · Phase 3 double-blind randomised trial | Adults with BMI ≥30, or ≥27 with an obesity-related condition | Up to 6.0 mg | Subcutaneous | Once weekly | Per trial protocol | Body weight | Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. |
| NCT06077864 — phase 3 cardiovascular outcomesClinical trial · Phase 3 outcomes trial, completed, no results posted | Adults with obesity (n=5531) | Per trial protocol | Subcutaneous | Once weekly | — | Cardiovascular outcomes | NCT06077864 — A Study to Test the Effect of Survodutide on Cardiovascular Outcomes |
Where sources disagree
- Survodutide is not approved by any regulator. Every dose above is trial dosing, reached by protocol-driven escalation with monitoring, not a maintenance regimen.
- It is a glucagon and GLP-1 receptor dual agonist, so its dose numbers are not comparable to semaglutide or tirzepatide despite the similar milligram range and weekly interval. Glucagon receptor agonism contributes a distinct effect and side-effect profile.
- Discontinuation in the phase 2 trial was substantial — only about 60% of participants completed 46 weeks — which is part of the dose-response picture and is usually omitted when the weight-loss percentages are quoted.
Reconstitution
Common research vial sizes: 10 mg, 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- Investigational - not yet established
- Injection Sites
- AbdomenThighUpper arm
- Concentration Example
- Investigational - not yet established
- Timing Notes
- Investigational; studied in obesity and MASH
- Expected Onset
- Investigational - onset under evaluation
Sequence & molecular data
| Molecular formula | C192H289N47O61 |
|---|---|
| Molecular weight | ≈4232 g/mol |
| CAS number | 2805997-46-8 |
| Half-life | ~6 days (once-weekly) |
| Appearance | Investigational sc formulation |
| Formulation | Lyophilized Powder |
| PubChem CID | 171378821 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Survodutide is a dual agonist at the glucagon and GLP-1 receptors, acylated for weekly dosing. GLP-1 receptor activation reduces energy intake through central appetite circuits and improves glucose-dependent insulin secretion, while glucagon receptor activation increases hepatic energy expenditure and stimulates fatty-acid oxidation in the liver. The hepatic component is the reason the class is being investigated in metabolic dysfunction-associated steatohepatitis as well as obesity, since glucagon signalling directly reduces hepatic lipid content. The design constraint is that unopposed glucagon agonism raises glucose, so the ratio of glucagon to GLP-1 activity determines whether the net glycaemic effect is favourable.
Origin
Synthetic peptide dual agonist.
Targets
Studies
- Survodutide Once Weekly for the Treatment of Adults with Obesity
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
- Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Regulatory & research status
Survodutide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
Benefits
Survodutide side effects
The effects below are those reported in Survodutide clinical trials; long-term safety data may still be limited.
Side Effects
- GI AEs
- Increased heart rate
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Survodutide: frequently asked questions
What is Survodutide?
Investigational dual agonist at the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma and studied in phase 3 trials for obesity and for metabolic dysfunction-associated steatohepatitis. The glucagon component acts directly on hepatocytes to increase energy expenditure and fat oxidation, which is why liver endpoints feature alongside weight. Not FDA-approved for any indication.
How does Survodutide work?
Survodutide is a dual agonist at the glucagon and GLP-1 receptors, acylated for weekly dosing. GLP-1 receptor activation reduces energy intake through central appetite circuits and improves glucose-dependent insulin secretion, while glucagon receptor activation increases hepatic energy expenditure and stimulates fatty-acid oxidation in the liver.
Is Survodutide FDA approved?
No. Survodutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of Survodutide?
Reported half-life for Survodutide is ~6 days (once-weekly). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Survodutide banned in sport?
Survodutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Survodutide?
Compounds most often compared with Survodutide include Retatrutide, Pemvidutide, Cotadutide and Mazdutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Survodutide Once Weekly for the Treatment of Adults with Obesity — N Engl J Med, 2026External reference
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes — Diabetes Obes Metab, 2026External reference
- Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity — Diabetes Obes Metab, 2026External reference
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) — Diabetes Obes Metab, 2026External reference
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial — Nat Med, 2026External reference
Related research, comparisons & guides
- Survodutide: The Other Glucagon Dual Agonist
- Peptides for Weight Loss: What Actually Has Evidence Behind It
- Retatrutide vs. Tirzepatide: Two Receptors or Three
- What Is Retatrutide? The Triple Agonist, Explained
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the Survodutide preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 6, 2026 · Version 3
This Survodutide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Survodutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →